paroxetine has been researched along with clozapine in 45 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (22.22) | 18.2507 |
2000's | 21 (46.67) | 29.6817 |
2010's | 14 (31.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Volpicelli, SA | 1 |
Green, AI; Patel, JK; Salzman, C; Tsuang, MT | 1 |
Abraham, JT; Brown, R; Meltzer, HY | 1 |
Ewald, R; Frank, UG; Joos, AA; Kaschka, WP; König, F; Mörike, KE | 1 |
Anghelescu, I; Härter, S; Hiemke, C; Szegedi, A; Weigmann, H; Wetzel, H; Wiesner, J | 1 |
Baldessarini, RJ; Centorrino, F; George, TP; Innamorato, L; Sernyak, MJ | 1 |
Altamura, AC; Bignotti, S; Curreli, R; Pioli, R; Tura, G | 1 |
Anghelescu, I; Hiemke, C; Schlegel, S; Szegedi, A; Weigmann, H; Wetzel, H | 1 |
Dekeyne, A; Girardon, S; Gobert, A; Millan, MJ | 1 |
Green, AI; Patel, JK; Strous, RD; Zimmet, S | 1 |
Ancione, M; Avenoso, A; Facciolá, G; Madia, A; Salemi, M; Scordo, MG; Spina, E | 1 |
Rehavi, M; Roz, N; Weizman, A | 1 |
Gaisler-Salomon, I; Green, A; Joel, D; Schiller, D; Weiner, I | 1 |
Borgheini, G | 1 |
Farah, RE; Makhoul, NM; Shai, MD | 1 |
Antonetti, DA; Maines, LW; Smith, CD; Wolpert, EB | 1 |
Asai, Y; Ichimiya, T; Inoue, M; Koyama, T; Kusumi, I; Sudo, Y; Suhara, T; Takahashi, Y; Takano, A; Yasuno, F | 1 |
Bernabei, R; Capurso, S; Gambassi, G; Liperoti, R; Tarsitani, P | 1 |
Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
Knopf, U; Kuwilsky, A; Zink, M | 1 |
Gross, G; Groth, I; Jongen-Relo, A; Rex, A; Wicke, KM | 1 |
2 review(s) available for paroxetine and clozapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Topics: Anticonvulsants; Biological Availability; Clinical Trials as Topic; Clozapine; Diazepam; Drug Approval; Drugs, Generic; Excipients; Humans; Paroxetine; Psychotropic Drugs; Therapeutic Equivalency | 2003 |
4 trial(s) available for paroxetine and clozapine
Article | Year |
---|---|
Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Smoking | 1998 |
Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Paroxetine; Prospective Studies; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 1998 |
Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.
Topics: Adult; Clozapine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Psychotic Disorders; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sertraline | 2000 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
39 other study(ies) available for paroxetine and clozapine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Affective Disorders, Psychotic; Aged; Ambulatory Care; Clozapine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Middle Aged; Paroxetine; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Stimulation, Chemical | 1996 |
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine.
Topics: Chronic Disease; Clozapine; Drug Therapy, Combination; Humans; Middle Aged; Paroxetine; Risperidone; Schizophrenia | 1997 |
Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Neurologic Examination; Paroxetine; Serotonin Receptor Agonists; Sumatriptan | 1997 |
Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Blood Pressure; Central Nervous System Diseases; Clozapine; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Dysthymic Disorder; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1997 |
Leukopenia associated with addition of paroxetine to clozapine.
Topics: Adult; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukopenia; Middle Aged; Paroxetine; Psychotic Disorders | 1998 |
Depressive symptomatology during clozapine treatment: two case reports.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clomipramine; Clozapine; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Schizophrenia | 1998 |
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
Topics: Animals; Biogenic Monoamines; Cerebral Cortex; Citalopram; Clozapine; Corpus Striatum; Diazepam; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; GABA Agents; Male; Norepinephrine; Nucleus Accumbens; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1999 |
Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.
Topics: Antipsychotic Agents; Clozapine; Comorbidity; Drug Therapy, Combination; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Schizophrenia; Schizophrenic Psychology; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
Topics: Animals; Antipsychotic Agents; Binding Sites; Biological Transport; Brain; Brain Chemistry; Clozapine; Drug Administration Schedule; Fluoxetine; Haloperidol; In Situ Hybridization; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Paroxetine; Piperazines; Rats; Tetrabenazine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2002 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Benzamides; Clozapine; Cyclosporine; Diclofenac; Drug Eruptions; Female; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nimodipine; Paroxetine; Piperazines; Polyethylene Glycols; Prednisolone; Pyrimidines; Recombinant Proteins; Salicylamides; Spironolactone; Thioridazine; Vinblastine; Vinorelbine | 2003 |
A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Clozapine; Conditioning, Psychological; Haloperidol; Imipramine; Inhibition, Psychological; Male; Models, Animal; Olanzapine; Paroxetine; Pirenzepine; Rats; Rats, Wistar; Swimming | 2003 |
Fatal venous thromboembolism associated with antipsychotic therapy.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Blood Coagulation; Clozapine; Drug Interactions; Fatal Outcome; Female; Humans; Middle Aged; Paroxetine; Pulmonary Embolism; Venous Thrombosis | 2004 |
Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells.
Topics: Animals; Anti-Inflammatory Agents; Anticonvulsants; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carbamazepine; Cattle; Cell Separation; Cells, Cultured; Cerebral Cortex; Clozapine; Endothelial Cells; Hydrocortisone; Paroxetine; Phenytoin; Rats; Retina; Selective Serotonin Reuptake Inhibitors | 2005 |
Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations.
Topics: Adult; Antipsychotic Agents; Carbon Isotopes; Chromatography, High Pressure Liquid; Clozapine; Computer Simulation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; Fluvoxamine; Humans; Male; Paroxetine; Positron-Emission Tomography; Pyrrolidines; Receptors, Dopamine D2; Salicylamides; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Time Factors | 2006 |
Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine.
Topics: Aged; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Fatal Outcome; Humans; Male; Neuroleptic Malignant Syndrome; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2006 |
Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2007 |
The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Clozapine; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Investigational; Fluoxetine; Guinea Pigs; Injections, Intraperitoneal; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Selective Serotonin Reuptake Inhibitors; Swimming; Tranylcypromine | 2007 |